Mono- and bis-thiazolium salts have potent antimalarial activity

Journal of Medicinal Chemistry

Volumn 48, Issue 10, 2005, Pages 3639-3643

  Hamzé, Abdallah ^a   Rubi, Eric ^a   Arnal, Pascal ^a   Boisbrun, Michel ^a,c   Carcel, Carole ^a   Salom Roig, Xavier ^a   Maynadier, Marjorie ^b   Wein, Sharon ^b   Vial, Henri ^b   Calas, Michèle ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c INSTITUT JEAN LAMOUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; BIS THIAZOLIUM SALT; MONO THIAZOLIUM SALT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VINCKEI; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; FEMALE; MALARIA; MICE; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 20844453564     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0492608     Document Type: Article

References (32)

1. (a) Breman, J. G. The Ears of the Hippopotamus: Manifestations, Determinants, and Estimates of the Malaria Burden. Am. J. Trop. Med. Hyg. 2001, 64, 1-11.
2. (b) Guerin, P. J.; Olliaro, P.; Nosten, F.; Druilhe, P.; Laxminarayan, R.; Binka, F.; Kilama, W. L.; Ford, N.; White, N. J. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect. Dis. 2002, 2, 564-573.
3. Hay, S. I.; Guerra, C. A.; Tatem, A. J.; Noor, A. M.; Snow, R. W. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 2004, 4, 327-336.
4. (a) Africa malaria report. WHO/33 25 April 2003.
5. (b) Mount, A. M.; Mwapasa, V.; Elliott, S. R.; Beeson, J. G.; Tadesse, E.; Lema, V. M.; Molyneux, M. E.; Meshnick, S. R.; Rogerson, S. J. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004, 363, 1860-1870.
6. (a) White, N. J. Antimalarial drug resistance. J. Clin. Invest. 2004, 113, 1084-1092.
7. (b) Biagini, G. A.; O'Neill, P. M.; Nzila, A.; Ward, S. A.; Bray, P. G. Antimalarial chemotherapy: young guns or back to the future? Trends in Parasitology 2003, 19, 479-487.
8. Haynes, R. K. Artemisinin and derivatives: the future for malaria treatment? Curr. Opin. Infec. Dis. 2001, 14, 719-726.
9. Borstnik, K.; Paik, I. H.; Posner, G. H. Malaria: new chemotherapeutic peroxide drugs. Mini-Rev. Med. Chem. 2002, 2, 573-583.
10. (a) Fidock, D. A.; Rosenthal, P. J.; Croft, S. L.; Brun, R.; Nwaka, S. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov. 2004, 3, 509-520.
11. (b) Butler, D.; Maurice, J.; O'Brien, C. Time to put malaria control on the global agenda. Nature 1897, 386, 535-541.
12. Calas, M.; Cordina, G.; Bompart, J.; Ben Baru, M.; Jei, T.; Ancelin, M. L.; Vial, H. Antimalarial Activity of Molecules Interfering with Plasmodium falciparum Phospholipid Metabolism. Structure-Activity Relationship Analysis. J. Med. Chem. 1997, 40, 3557-3566.
13. Calas, M.; Ancelin, M. L.; Cordina, G.; Portefaix, P.; Piquet, G.; Vidal-Sailhan, V.; Vial, H. Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between Mono- and Bisquaternary ammonium salts. J. Med. Chem. 2000, 43, 505-516.
14. Wengelnik, K.; Vidal, V.; Ancelin, M. L.; Cathiard, A. M.; Morgat, J. L.; Kocken, C. H.; Calas, M.; Herrera, S.; Thomas, A. W.; Vial, H. J. A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science 2002, 295, 1311-1314.
15. Ancelin, M. L.; Calas, M.; Bompart, J.; Cordina, G.; Martin, D.; Bari, M. B.; Jei, T.; Druilhe, P.; Vial, H. Antimalarial activity of 77 phospholipid polar head analogues: close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth. Blood 1998, 91 (4), 1426-1437.
16. Vial, H.; Ancelin, M. L. in Malaria: Parasite Biology, Pathogenesis, Protection. Sherman, I. W., Ed.; American Society for Microbiology: Washington, DC, 1998; pp 159-175.
17. Vial, H.; Ancelin, M. L. Malarials Lipids, an overview. In Subcellular Biochemistry; Avila, J. L.; Harris, J. R., Eds.; Plenum Press: New York, 1992; Vol. 18, pp 259-306.
18. All animal study protocols were performed in accordance with legislative guidelines. All nonhuman primate study protocols were evaluated and approved by independent animal care and use committees before the beginning of the studies.
19. Ainscow, T. A.; Belmont, M. R.; Henshall, J. L.; Hooper, R. M. and Simmonds, D. J. Synthesis of four n-alkanes with terminal dipolar substituents. Tetrahedron 1987, 43 (1), 115-122.
20. Schultz, W. E.; Machula, H. J.; Feinendegen, L. E. Synthesis of 1-carbon-14-17-iodoheptadecanoïc acid. J. Radioanal. Nucl. Chem. 1989, 135, 199-205.
21. Cram, D. J.; Allinger, N. L.; Steinberg, H. Macro rings. VII. The spectral consequences of bringing two benzene rings face to face. J. Am. Chem. Soc. 1954, 76, 6132-6141.
22. Wood, W. The preparation of n-octadecylamine hydrochloride. J. Chem. Soc., Abstracts, 1953, 3327.
23. Svendsen, A.; Boll, P. M. Naturally occurring lactones and lactams. V. Halogenated β-keto esters as starting materials for the synthesis of tetronic acids. Tetrahedron 1973, 29, 4251-4258.
24. Costa, T.; Wuster, M.; Herz, A.; Shimohigashi, Y.; Chen, H. C.; Rodbard, D. Receptor binding and biological activity of bivalent enkephalins. Biochem. Pharmacol. 1985, 34, 25-30.
25. Portoghese, P. S. Bivalent ligands and the message address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 10, 230-235.
26. Cheronis, J. C.; Whalley, E. T.; Nguyen, K. T.; Eubanks, S. R.; Allen, L. G.; Duggan, M. J.; Loy, S. D.; Bonham, K. A.; Blodgett, J. K. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimmers. J. Med. Chem. 1992, 35, 1563-72.
27. Portoghese, P. S.; Ronsisvalle, G.; Larson, D. L.; Yim, C. B.; Sayre L. M.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands as receptor probes. Life Sci. 1982, 31, 1283-1286.
28. Portoghese, P. S. Bivalent ligands in the development of selective opioid receptor antagonists. In Trends in Medicinal Chemistry; Mutschler, E., Winterfeldt, E., Eds.; VCH Verlagsgesellschaft: Weinheim, 1987, pp 327-336.
29. Shimazaki, N.; Shima, I.; Hemmi, K.; Tsurumi, Y.; Hashimoto, M. Diketopiperazine derivatives, a new series of platelet-activating factor inhibitors. Chem. Pharm. Bull. 1987, 35, 3527-3530.
30. Thomson, A. D.; Frank, O.; Baker, H.; Leevy, C. M. Thiamine propyl disulfide: absorption and utilization. Ann. Intern. Med. 1971, 74, 529-534.
31. Ancelin, M. L.; Calas, M.; Bonhoure, A.; Herbuté, S.; Vial, H. Potent inhibitors of Plasmodium phospholipid metabolism with a broad spectrum of in vitro antimalarial activities. Antimicrob. Agents Chemother. 2003, 47, 2590-7.
32. Ancelin, M. L.; Calas, M.; Vidal-Sailhan, V.; Herbuté, S., Ringwald, P.; Vial, H. In vivo antimalarial activities of mono-and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. Antimicrob. Agents Chemother. 2003, 47, 2598-605.